1. Pink Sheet
  2. >>Legal & IP

FTC’s Test Case Opposing Amgen-Horizon Deal Ends With No-Bundling Agreement

 
• By Brenda Sandburg

Commission pursued merger challenge to halt pharma practices it believes can stifle competition and keep drug prices high. Other large biopharma transactions may face similar challenges as FTC pursues its new merger program.

merger horizon
Federal Trade Commission reaches consent order allowing Amgen's acquisition of Horizon Therapeutics • Source: Shutterstock

The US Federal Trade Commission’s legal challenge to block Amgen, Inc.’s proposed acquisition of Horizon Therapeutics plc was resolved with the agency formalizing Amgen’s commitment not to bundle its products with Horizon’s orphan drugs. Future pharma mergers may face similar hurdles as the agency aims to curtail practices that could make it harder for rivals to compete post-merger.

The FTC announced on 1 September that it had reached an agreement-containing consent order which includes a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

FDA Adcomms Are Back: Four Cancer Drugs, COVID-19 Vaccine Formulations To Get Reviews

 
• By Sue Sutter and Bridget Silverman

The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.